Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery.

We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our Core Values drive the way we work together:

Dare to Cure
Break Boundaries
Beyond Yourself
Prepare & Execute Relentlessly

Join us in creating the future of genetic medicine.

GENERAL SUMMARY

4D Molecular Therapeutics (4DMT) is a late-stage clinical gene therapy company advancing a potentially transformative pipeline toward its first Biologics License Application (BLA) & commercial launch. Reporting to the Sr. Director, IT Business Partner, R&D, the Director serves as a broad deputy across R&D & helps translate the integrated R&D technology strategy into delivery across clinical, regulatory, safety, laboratory, scientific informatics, manufacturing, supply, quality & facility systems, data & integrations required for pivotal development, BLA submission, inspection readiness & launch.

This role partners across PreClinical R&D, Technical Operations (including Supply Management), Clinical Science & Operations, Data Sciences & Biostatistics, Quality, Regulatory Affairs, Pharmacovigilance, Program Management, Facilities & Medical Affairs. The Director supports the objectives of the Sr. Director by managing assigned platforms, initiatives & workstreams; coordinating vendors, contractors & project teams; & connecting functional needs to the integrated R&D roadmap across the research-to-commercial lifecycle.

Success will be measured by stakeholder satisfaction; delivery of assigned roadmap commitments on schedule & within budget; inspection, submission, manufacturing, supply & launch readiness; availability, adoption & validated-state performance of assigned platforms; effective risk, vendor & financial management; & measurable business value from compliant data, analytics, automation & AI.

MAJOR DUTIES & RESPONSIBILITIES

Serve as a broad deputy to the Sr. Director, IT Business Partner, R&D, helping execute the integrated R&D technology strategy & representing R&D IT in assigned forums, initiatives & escalations.
Serve as IT business partner & system owner for assigned R&D platforms, accountable for roadmap execution, implementation, integrations, validated-state maintenance, service performance, security, data integrity, adoption & lifecycle planning within the strategy, architecture, investment priorities & governance established by the Sr. Director.